4//SEC Filing
Yen Yun 4
Accession 0001493152-23-023930
CIK 0001335105other
Filed
Jul 6, 8:00 PM ET
Accepted
Jul 7, 10:58 AM ET
Size
13.2 KB
Accession
0001493152-23-023930
Insider Transaction Report
Form 4
Yen Yun
Director
Transactions
- Award
Options to Purchase Common Stock
2023-06-30+10,000→ 10,000 totalExercise: $5.88From: 2023-06-30Exp: 2028-06-30→ Common (10,000 underlying)
Holdings
- 10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying) - 5,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying) - 5,263(indirect: By Sino-American Cancer FDD)
Warrants to Purchase Common Stock
Exercise: $57.00From: 2020-11-30Exp: 2025-11-30→ Common (5,263 underlying) - 3,333
Options to Purchase Common Stock
Exercise: $16.80From: 2018-08-04Exp: 2023-08-04→ Common (3,333 underlying) - 833
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying)
Footnotes (1)
- [F1]Effective June 30, 2023, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2023). Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of Common Stock set forth above have been adjusted to reflect the reverse split.
Documents
Issuer
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK 0001335105
Entity typeother
Related Parties
1- filerCIK 0001684584
Filing Metadata
- Form type
- 4
- Filed
- Jul 6, 8:00 PM ET
- Accepted
- Jul 7, 10:58 AM ET
- Size
- 13.2 KB